Table of Content


Introduction
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Overview
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Development
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Therapeutics Assessment
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Companies Involved in Therapeutics Development
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Drug Profiles
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Dormant Products
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Discontinued Products
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Product Development Milestones
Appendix



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indications, H1 2020
Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Antisense Therapeutics Ltd, H1 2020
Pipeline by Aviara Pharmaceuticals Inc, H1 2020
Pipeline by AxeroVision Inc, H1 2020
Pipeline by Biogen Inc, H1 2020
Pipeline by C4X Discovery Holdings Plc, H1 2020
Pipeline by EA Pharma Co Ltd, H1 2020
Pipeline by Feramda Ltd, H1 2020
Pipeline by Genentech Inc, H1 2020
Pipeline by Gilead Sciences Inc, H1 2020
Pipeline by Immunwork Inc, H1 2020
Pipeline by Morphic Holding Inc, H1 2020
Pipeline by Polpharma Biologics, H1 2020
Pipeline by Protagonist Therapeutics Inc, H1 2020
Pipeline by Regenerative Arthritis & Bone Medicine Inc, H1 2020
Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
Pipeline by Tolerion Inc, H1 2020
Pipeline by Zealand Pharma AS, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Dormant Products, H1 2020 (Contd..2), H1 2020
Discontinued Products, H1 2020